Report of Foreign Issuer (6-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September 2019

 

Commission File Number: 001-38764

 

Aptorum Group Limited

 

17^th Floor, Guangdong Investment Tower

148 Connaught Road Central

Hong Kong

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F  ☒            Form 40-F  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

  

 

 

 

 

The following exhibits are attached.

 

Exhibit		Description
99.1		Press Release dated September 9, 2019: Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2019
99.2		Corporate Presentation
99.3		Press Release dated September 9, 2019: Aptorum Group Has Initiated IND-Enabling Studies For Its ALS-4 Small Molecule Candidate For The Treatment Of Infections Caused By Staphylococcus Aureus Including MRSA
99.4		Press Release dated September 9, 2019: Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma

 

1 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: September 9, 2019

 

	Aptorum Group Limited
	By:	/s/ Sabrina Khan
		Sabrina Khan
		Chief Financial Officer

 

2 

 

 

EXHIBIT INDEX

  

Exhibit		Description
99.1		Press Release dated September 9, 2019: Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2019
99.2		Corporate Presentation
99.3		Press Release dated September 9, 2019: Aptorum Group Has Initiated IND-Enabling Studies For Its ALS-4 Small Molecule Candidate For The Treatment Of Infections Caused By Staphylococcus Aureus Including MRSA
99.4		Press Release dated September 9, 2019: Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma

  

  

 

3